The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment

• Published in: Growth hormone & IGF research 2015-08, Vol.25 (4), p.174-181
• Main Authors: Espelund, Ulrick, Grønbæk, Henning, Villadsen, Gerda Elisabeth, Simonsen, Kira, Vestergaard, Poul Frølund, Jørgensen, Jens Otto Lunde, Flyvbjerg, Allan, Vilstrup, Hendrik, Frystyk, Jan
• Format: Article
• Language: English
• Subjects: Adult; Advanced Basic Science; Aged; Aged, 80 and over; Biological assay; Biomarkers, Tumor - metabolism; Carcinoma, Hepatocellular - metabolism; Case-Control Studies; Endocrinology & Metabolism; Female; Hepatocellular carcinoma; Humans; Insulin-Like Growth Factor Binding Protein 2 - metabolism; Insulin-Like Growth Factor Binding Protein 3 - metabolism; Insulin-like growth factor binding proteins; Insulin-like growth factor I; Insulin-Like Growth Factor I - metabolism; Insulin-like growth factor II; Insulin-Like Growth Factor II - metabolism; Kinase receptor activation assay; Liver cirrhosis; Liver Cirrhosis - metabolism; Liver Neoplasms - metabolism; Male; Middle Aged; Protein Precursors - metabolism; Young Adult
• ISSN: 1096-6374; 1532-2238
• DOI: 10.1016/j.ghir.2015.05.002

Abstract Background Previous studies have demonstrated an elevated IGF-II mRNA expression and protein levels in tumors and blood from patients with hepatocellular carcinoma (HCC), hereby suggesting a role of IGF-II as a pathogenic marker of HCC. We hypothesized that in HCC, an increased IGF-II secretion would translate into an elevated circulating IGF bioactivity, which would normalize following treatment. Methods Patients with HCC (n = 39) were studied before and after radio-frequency ablation and/or transarterial chemo-embolization. Baseline data were compared to healthy subjects (n = 150) and patients with liver cirrhosis (n = 41). Serum levels of IGF ligands and IGF binding proteins (IGFBPs) were determined using gold standard methods as well as novel assays and compared to liver function tests and HCC treatment status. Results At baseline, HCC patients differed from cirrhosis patients and healthy controls regarding IGF-I (29 [23–37] vs. 12 [7–19] vs. 109 [103–116] μg/l), IGF-II (254 [224–288] vs. 118 [102–137] vs. 545 [525–566] μg/l) and IGF bioactivity (0.53 [0.41–0.68] vs. 0.29 [0.24–0.34] vs. 1.43 [1.33–1.53] μg/l) (mean [95% confidence interval], all age-adjusted P < 0.001). All variables but IGFBP-2 were strongly associated with liver status (MELD score), and accordingly, differences were either attenuated or disappeared when adjusted for MELD score. There was no effect of treatment on any IGF variables. Conclusions The marked differences in IGF and IGFBP levels between patients with HCC, liver cirrhosis and healthy subjects are mainly explained by variations in liver status. Therefore, this study questions the clinical utility of circulating IGF variables as markers of HCC.